Chinese Pharma Invests $1M in Israeli Company

Globes reported that Chinese pharmaceutical company Acebright Holdings Ltd. will invest $1 million in NasVax Ltd. (TLV: NSVX), a developer of immunotherapies.

As quoted in the market news:

The two companies also signed a nonbinding memorandum of understanding granting Acebright an exclusive license to develop and conduct clinical trials of NasVax’s Anti-CD3 technology for the treatment of non-alcoholic steatohepatitis (NASH), or fatty liver disease, only, and to commercialize it in the Far East, including China, Hong Kong, Korea, Thailand, the Philippines, and India, but excluding Japan.

Click here for the full article in Globes